🌟 Long-Term Results Show Promise for RP Therapy
At the 2025 ASRS meeting, researchers shared 2-year results showing that MCO-010, an optogenetic therapy, provided lasting vision improvements for patients with advanced retinitis pigmentosa. Unlike traditional gene therapies, MCO-010 is gene-agnostic, meaning it could help a broad range of patients regardless of mutation.

First Patients Treated in jCell RP Trial
jCyte has launched its Phase 2 JC02-88 trial testing jCell, a potential regenerative therapy for retinitis pigmentosa. This study could bring the first treatment option to the majority of RP patients, offering hope across all genetic subtypes.

FDA Fast Tracks Potential RP Treatment
Aldeyra’s ADX-2191 has received Fast Track Designation from the FDA for retinitis pigmentosa. With no approved treatments currently available for most RP patients, this milestone could help speed the development of a promising new therapy.

Hope for RP and Stargardt Disease
Nanoscope Therapeutics is advancing a one-time gene therapy designed to restore vision for patients with retinitis pigmentosa and Stargardt disease. If successful, this treatment could transform care for two conditions that currently have no approved therapies.

Stem Cell–Derived Retinal Sheets Trial for RP
A new clinical trial is testing DSP-3077, a one-time stem cell–derived retinal sheet implant, as a potential treatment for retinitis pigmentosa. This regenerative therapy could offer hope for patients regardless of genetic subtype. Learn how this groundbreaking study may shape the future of RP treatment.